Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.
Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.
For use as an intravenous source of water, electrolytes, and calories in patients who require fluid and electrolyte replacement and caloric intake,Off-label: treatment and prevention of hypovolemia, maintenance of fluid and electrolyte balance in perioperative settings
Fluid and electrolyte replacement,Maintenance of hydration and electrolyte balance in patients unable to tolerate oral intake,Correction of hypovolemia,Mild to moderate metabolic acidosis
IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.
Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.
Not applicable as it is a balanced electrolyte solution with dextrose. Components distribute and are eliminated rapidly; dextrose half-life ~15-30 minutes in normoglycemia.
Not applicable as a fixed drug. Electrolytes have no defined half-life; dextrose is rapidly cleared with a metabolic half-life of approximately 5-10 minutes due to insulin-mediated uptake.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, producing energy. Acetate and gluconate are metabolized in the liver and tissues to bicarbonate. Electrolytes are not metabolized but are excreted or reutilized.
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, primarily in the liver; insulin promotes cellular uptake. Electrolytes are not metabolized but are excreted or reabsorbed by the kidneys.
Components are excreted renally. Dextrose is metabolized; electrolytes are eliminated via kidneys (sodium, chloride, acetate, gluconate, magnesium, potassium). No biliary or fecal elimination.
Electrolytes and dextrose are primarily excreted renally. Potassium, sodium, chloride, and magnesium are eliminated via kidneys. Dextrose is metabolized to CO2 and water, with negligible renal excretion. Biliary/fecal elimination is minimal (<5%).
Electrolytes and dextrose have negligible protein binding (<1%). No significant binding.
Negligible for electrolytes and dextrose (<5%).
Vd approximates extracellular fluid volume: ~0.15-0.25 L/kg for electrolyte components; dextrose distributes into total body water (~0.6 L/kg).
Not applicable as a single compound. Electrolytes distribute primarily in extracellular fluid (0.2 L/kg for sodium), total body water (0.6 L/kg for water). Dextrose distributes in total body water (0.55 L/kg).
Intravenous: 100% (by definition). Not administered via other routes.
Intravenous: 100%.
If GFR < 30 m L/min, reduce infusion rate by 50% and monitor potassium and phosphate levels closely; avoid in severe renal impairment if hyperkalemia or hyperphosphatemia is present.
No specific dose adjustment required; monitor serum electrolytes and fluid status in renal impairment due to risk of hyperkalemia, hypernatremia, or fluid overload.
No specific Child-Pugh-based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances.
No specific dose adjustment; use with caution in severe hepatic impairment due to potential for fluid and electrolyte disturbances.
Neonates and children: IV infusion at 5-10 m L/kg/hour, titrated to clinical need; maximum rate 20 m L/kg/hour; monitor electrolytes frequently.
Weight-based: 2-6 m L/kg/hour or as per Holliday-Segar method for maintenance; monitor serum electrolytes closely.
Start at lower infusion rate (5-10 m L/kg/hour) due to age-related decline in renal function; reassess fluid status regularly to avoid volume overload.
Use with caution; consider lower initial rates due to reduced renal function and increased risk of fluid overload; monitor electrolytes and volume status.
Not approved for use in patients with known hypersensitivity to any component. Not for use as a primary source of nutrition in neonates or low birth weight infants due to risk of aluminum toxicity.
None for this product; however, caution is required in patients with congestive heart failure, renal impairment, or conditions predisposing to electrolyte imbalances.
Risk of fluid overload and electrolyte disturbances, especially in patients with renal impairment, heart failure, or severe dehydration,May cause hyperglycemia, particularly in diabetic patients,Monitor serum electrolytes, blood glucose, and fluid balance during infusion,Aluminum toxicity with prolonged use in renal impairment,Do not administer simultaneously with blood products through same IV line
Risk of fluid overload in patients with compromised cardiac or renal function,Risk of electrolyte imbalances (hyperkalemia, hyponatremia, hypernatremia),Administration may cause phlebitis or thrombosis,Monitor serum electrolytes, glucose, and fluid balance,Use with caution in patients with diabetes or glucose intolerance,Not for use when hyperosmolality is present
Hypersensitivity to any component,Clinically significant hyperglycemia,Severe hyponatremia, hyperkalemia, or hypercalcemia,Patients with anuria or severe oliguria not due to hypovolemia
Hyperkalemia,Severe renal impairment (oliguria or anuria),Severe metabolic alkalosis,Hypersensitivity to any component,Patients with known glucose-6-phosphate dehydrogenase deficiency (relative, due to potential for Heinz body formation)
No direct food interactions. However, dextrose content may affect blood glucose; patients with diabetes should monitor glucose levels closely and adjust insulin/oral hypoglycemic agents as directed. Use with caution in patients on sodium or potassium-modifying diets.
No known food interactions. However, monitor dietary intake of sodium, potassium, and chloride to avoid electrolyte imbalances.
Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolytes and dextrose are physiological substances. However, careful monitoring is required during pregnancy to avoid fluid overload, electrolyte imbalances, or hyperglycemia, which could indirectly affect fetal development. No specific trimester-specific risks are identified.
Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological constituents. However, maternal hyperglycemia from dextrose may increase fetal risks including macrosomia and congenital anomalies if glucose not controlled. First trimester: no direct teratogenicity, but dextrose-induced hyperglycemia may be associated with neural tube defects. Second/third trimester: risk of fetal hyperinsulinemia, macrosomia, neonatal hypoglycemia if maternal glucose elevated.
Plasma-Lyte 148 and Dextrose 5% is compatible with breastfeeding. Electrolytes and dextrose are normal blood components that are transferred into breast milk in small amounts, not expected to cause adverse effects in the infant. M/P ratio is not applicable as it is a mixture of physiological substances.
Components are normal constituents of human milk. No specific M/P ratio data; dextrose, sodium, potassium, magnesium, chloride, acetate, gluconate are expected to transfer minimally. Use is compatible with breastfeeding. Monitor infant for electrolyte balance only if maternal levels are abnormal.
Pharmacokinetic changes during pregnancy (increased plasma volume, altered renal function) may require adjustments in infusion rate and total volume to maintain electrolyte and glucose homeostasis. Dose should be individualized based on maternal weight, clinical status, and laboratory values; no fixed dose adjustment is required.
Pregnancy increases plasma volume and glomerular filtration rate; may require higher infusion rates to achieve desired electrolyte balance. Dextrose load may need adjustment to avoid maternal hyperglycemia, especially in gestational diabetes. No dose changes for electrolyte components themselves; monitor clinical response and serum levels.
PLASMA-LYTE 148 and Dextrose 5% is an isotonic solution containing electrolytes and dextrose. Use within 24 hours of spiking the container. Avoid administering through the same line as blood products due to risk of hemolysis from electrolyte content. Monitor serum glucose, electrolytes, and fluid balance, especially in patients with impaired renal function, diabetes, or heart failure. The solution has a p H of ~5.5; consider compatibility with co-administered drugs.
ISOLYTE H IN DEXTROSE 5% is a hypertonic solution (approximately 554 m Osm/L) that provides free water, electrolytes, and calories. Use caution in patients with renal impairment or those at risk for fluid overload. Monitor serum sodium, potassium, chloride, and glucose levels during infusion. Do not administer if solution is discolored or contains particulate matter. Compatible with most IV lines but avoid adding other drugs without checking compatibility.
This solution provides fluids and sugar to help maintain hydration and energy.,Tell your healthcare provider if you have diabetes, heart problems, or kidney disease.,You may experience swelling, shortness of breath, or changes in urination; report these immediately.,Your blood sugar and electrolyte levels will be monitored during treatment.,Do not use this solution if it is cloudy, discolored, or contains particles.
This solution is given through a vein to provide fluids, electrolytes, and sugar.,Tell your healthcare provider if you have kidney problems, heart issues, or if you are on a low-sodium or low-potassium diet.,Report any signs of fluid overload such as swelling, shortness of breath, or rapid weight gain.,You may need blood tests to check your body's electrolyte levels and blood sugar.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte H in Dextrose 5% provides a balanced electrolyte solution with glucose to maintain fluid and electrolyte homeostasis. Dextrose is metabolized to carbon dioxide and water, providing calories. Electrolytes replenish losses and maintain acid-base balance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is: IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.. The standard adult dose of ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; rate determined by clinical condition, electrolyte requirements, and fluid balance. Typical adult maintenance: 100-200 m L/hour. Maximum infusion rate: 1000 m L/hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolyte. ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Isolyte H in Dextrose 5% is a balanced electrolyte solution with multiple electrolytes and 5% dextrose. Teratogenic risk: minimal due to components being normal physiological const. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.